Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15259907 | 1.00 | F7 (0.90) | F7F3 | |
| SCHEMBL15259751 | 1.00 | F7 (0.90) | F7F3 | |
| SCHEMBL3093181 | 0.95 | F7 (1.00) | F7F3 | |
| SCHEMBL3068890 | 0.95 | F7 (1.00) | F7F3 | |
| SCHEMBL3068885 | 0.95 | F7 (1.00) | F7F3 | |
| SCHEMBL15259922 | 0.90 | F7 (0.79) | F7F3 | |
| SCHEMBL15259872 | 0.90 | F7 (0.79) | F7F3 | |
| SCHEMBL15259765 | 0.88 | F7 (0.90) | F7F3 | |
| SCHEMBL15259846 | 0.88 | F7 (0.90) | F7F3 | |
| SCHEMBL15259843 | 0.86 | F7 (0.90) | F7F3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2061756-B1 | 2-AMINOCARBONYLPHENYLAMINO-2-PHENILACETAMIDES AS FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | BRISTOL MYERS SQUIBB CO (US) | 2013-09-25 | — | — | EP | claimed |
| US-20140357567-A1 | METHODS FOR TREATING CANCERS USING ORAL FORMULATIONS OF CYTIDINE ANALOGS | CELGENE CORPORATION | 2014-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140357567-A1 | METHODS FOR TREATING CANCERS USING ORAL FORMULATIONS OF CYTIDINE ANALOGS | CDA, DCTD, DCK | F7 2652/4885F3 4196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.